Downregulation of muscle Ppargc1a and Slc2a4 expression in the BC group was counteracted in the BC+MET group, whereas observed gene inductions by single BC and MET treatments were not additive in the cotreatment group. This evidence concerns the gene SLC2A4 and breast cancer.